Among the current popular pharmacotherapies for glucose control, comorbidity management, and obesity in adults with T1DM, GLP-1 and dual GLP-1/GIP receptor agonists may offer promising benefits, particularly in improving insulin sensitivity and aiding in weight management, though their long-term effects in T1DM still require further investigation [3]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.